"10.1371_journal.pmed.1001510","plos medicine","2013-09-03T00:00:00Z","Amanda Mocroft; Jens D Lundgren; Miriam Lewis Sabin; Antonella d'Arminio Monforte; Norbert Brockmeyer; Jordi Casabona; Antonella Castagna; Dominique Costagliola; Francois Dabis; Stéphane De Wit; Gerd Fätkenheuer; Hansjakob Furrer; Anne M Johnson; Marios K Lazanas; Catherine Leport; Santiago Moreno; Niels Obel; Frank A Post; Joanne Reekie; Peter Reiss; Caroline Sabin; Adriane Skaletz-Rorowski; Ignacio Suarez-Lozano; Carlo Torti; Josiane Warszawski; Robert Zangerle; Céline Fabre-Colin; Jesper Kjaer; Genevieve Chene; Jesper Grarup; Ole Kirk; Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord","Department of Infection and Population Health, University College London, London, United Kingdom; Copenhagen HIV programme, University of Copenhagen, Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital/Rigshospitalet, Copenhagen, Denmark; Department of Health Sciences, Institute of Infectious Diseases, Milan, Italy; Department of Dermatology, Venerology, and Allergology, St. Josef Hospital, Ruhr-Universität Bochum, Bochum, Germany; CEEISCAT (Agència de Salut Pública de Catalunya) and CIBERESP, Badalona, Catalonia, Spain; Department of Infectious Diseases IRCCS San Raffaele, Milan, Italy; UPMC Université Paris 06, UMR_S 943, Paris, France; INSERM, UMR_S 943, Paris, France; Université of Bordeaux, ISPED, Centre Inserm, U897–Epidémiologie–Biostatistiques, Bordeaux, France; Inserm U897–Epidémiologie–Biostatistiques, Bordeaux, France; Saint-Pierre Hospital, Brussels, Belgium; Universität Köln, Cologne, Germany; Department of Infectious Diseases, Bern University Hospital and University of Bern, Bern, Switzerland; 3rd Internal Medicine Department and Infectious Disease Unit, Red Cross General Hospital of Athens, Greece; Université Paris Diderot, Sorbonne Paris Cité, UMR 738, Paris, France; INSERM, UMR 738, Paris, France; Department of Infectious Diseases. University Hospital Ramón y Cajal, IRYCIS, Madrid, Spain; Kings College London School of Medicine, London, United Kingdom; The Kirby Institute, University of New South Wales, Sydney, Australia; Academisch Medisch Centrum bij de Universiteit van Amsterdam, Amsterdam, The Netherlands; Stichting HIV Monitoring, Amsterdam, The Netherlands; German Competence Network for HIV/AIDS, St. Josef Hospital, Ruhr-Universität Bochum, Bochum, Germany; Infectious Diseases Unit, Complejo Hospitalario de Huelva, Spanish VACH Cohort, Spain; University Division of Infectious and Tropical Diseases, University and Spedali Civili of Brescia, Brescia, Italy; Department of Medical and Surgical Sciences, Unit of Infectious Diseases, University Magna Graecia, Catanzaro, Italy; INSERM CESP U1018, Université Paris-Sud, AP-HP Public Health Department, Le Kremlin-Bicêtre, France; Medical University Innsbruck, Innsbruck, Austria; Université de Bordeaux, ISPED, Centre INSERM U897-Epidémiologie Statistique, Bordeaux, France; INSERM, ISPED, Centre INSERM U897-Epidémiologie Statistique, Bordeaux, France","¶ Membership of the Late Presenters Working Group and the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study is provided in the Acknowledgments.","AM has received lecture fees, honoraria, and/or consultancies from Pfizer, BI, BMS, Merck, and Gilead. AdA is an advisory board member of BMS, Jannsen, Gilead, and ViiV. GF has received honoraria for lectures and advisory boards from Abbott, Bristol-Myers Squibb, Gilead, Janssen-Cilag, and Merck Sharp & Dohme. Research grant to GF from the German Federal Ministry of Education and Research (BMBF) 01KI1017. AJ is a Governor of the Wellcome Trust, a charitable research funding body; in 2011 was a specialist adviser to House of Lords Select Committee on HIV/AIDS; is a member of the UK Expert Advisory Group on AIDS; receives research grant funding from the UK Medical Research Council, Wellcome Trust, UK National Institute for Health Research, and Department of Health. CL has received these research grants: ANRS CMIT soutien (Aproco-Copilote ANRS CO08 HIV cohort, 1997–2012); IMMI (Cohort Fluco A(H1N1) pandemic influenza, 2009–2012); Ministère de la Santé PHRC (Bivir influenza trial, Oseltamivir Zanamivir, 2006–2012). CS has received funding for Advisory Board membership, speaker panels, and provision of educational materials for Gilead Sciences, Abbott Pharmaceuticals, ViiV, Merck Sharp & Dohme, Janssen-Cilag, and Bristol-Myers Squibb. CT has received honoraria to act as speaker at CME conferences on antiretroviral therapy and HIV disease management from several companies producing antiretroviral drugs, received travel grants to participate in scientific conferences, and acted as scientific consultant for the same companies. GC has had scientific responsibilities in projects receiving specific grant support from the French Agency for Research on AIDS and Viral Hepatitis (ANRS), the European Commission (Framework Program 7), UK Medical Research Council, US National Institute of Health (NIH), Fondation Plan Alzheimer, Gilead, Tibotec, Boehringer Ingelheim, GlaxoSmithKline, Roche, Pfizer, Merck, Abbott, Bristol-Myers Squibb, Janssen, ViiV Healthcare – these grants are managed through her Institution or a non-profit society. GC also serves as Academic Editor on PLOS ONE and is on the editorial board of the BMC Infectious Diseases Journal. OK has received honoraria, consultancy, lecture fees, and travel grants from Abbott Laboratories, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp & Dohme, Roche, and ViiV Healthcare, and has served/is serving on Advisory Boards for Gilead Sciences, Merck Sharp & Dohme, and ViiV Healthcare. No other competing interests have been declared.","2013","09","Amanda Mocroft","AM",32,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
